vs
EXACT SCIENCES CORP（EXAS）与利氏兄弟拍卖行（RBA）财务数据对比。点击上方公司名可切换其他公司
利氏兄弟拍卖行的季度营收约是EXACT SCIENCES CORP的1.4倍（$1.2B vs $878.4M），利氏兄弟拍卖行净利率更高（9.1% vs -9.8%，领先18.9%），EXACT SCIENCES CORP同比增速更快（23.1% vs 5.4%），利氏兄弟拍卖行自由现金流更多（$186.5M vs $120.4M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs 6.3%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
利氏兄弟拍卖行（股票代码RBA）是全球知名的工业资产拍卖服务商，注册地位于加拿大，属公开上市企业，总部设在美国伊利诺伊州韦斯特切斯特，普通股同时在多伦多证券交易所与纽约证券交易所挂牌交易。
EXAS vs RBA — 直观对比
营收规模更大
RBA
是对方的1.4倍
$878.4M
营收增速更快
EXAS
高出17.7%
5.4%
净利率更高
RBA
高出18.9%
-9.8%
自由现金流更多
RBA
多$66.1M
$120.4M
两年增速更快
EXAS
近两年复合增速
6.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $1.2B |
| 净利润 | $-86.0M | $109.7M |
| 毛利率 | 70.1% | — |
| 营业利润率 | -9.4% | 14.7% |
| 净利率 | -9.8% | 9.1% |
| 营收同比 | 23.1% | 5.4% |
| 净利润同比 | 90.1% | -7.4% |
| 每股收益（稀释后） | $-0.45 | $0.53 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASRBA
| Q4 25 | $878.4M | $1.2B | ||
| Q3 25 | $850.7M | $1.1B | ||
| Q2 25 | $811.1M | $1.2B | ||
| Q1 25 | $706.8M | $1.1B | ||
| Q4 24 | $713.4M | $1.1B | ||
| Q3 24 | $708.7M | $981.8M | ||
| Q2 24 | $699.3M | $1.1B | ||
| Q1 24 | $637.5M | $1.1B |
净利润EXASRBA
| Q4 25 | $-86.0M | $109.7M | ||
| Q3 25 | $-19.6M | $95.5M | ||
| Q2 25 | $-1.2M | $109.8M | ||
| Q1 25 | $-101.2M | $113.4M | ||
| Q4 24 | $-864.6M | $118.5M | ||
| Q3 24 | $-38.2M | $76.1M | ||
| Q2 24 | $-15.8M | $111.1M | ||
| Q1 24 | $-110.2M | $107.4M |
毛利率EXASRBA
| Q4 25 | 70.1% | — | ||
| Q3 25 | 68.6% | — | ||
| Q2 25 | 69.3% | — | ||
| Q1 25 | 70.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 69.8% | — | ||
| Q1 24 | 70.0% | — |
营业利润率EXASRBA
| Q4 25 | -9.4% | 14.7% | ||
| Q3 25 | -3.0% | 14.5% | ||
| Q2 25 | -0.3% | 15.9% | ||
| Q1 25 | -13.6% | 17.1% | ||
| Q4 24 | -122.8% | 18.1% | ||
| Q3 24 | -5.6% | 15.6% | ||
| Q2 24 | -3.8% | 18.4% | ||
| Q1 24 | -16.7% | 18.7% |
净利率EXASRBA
| Q4 25 | -9.8% | 9.1% | ||
| Q3 25 | -2.3% | 8.7% | ||
| Q2 25 | -0.1% | 9.3% | ||
| Q1 25 | -14.3% | 10.2% | ||
| Q4 24 | -121.2% | 10.4% | ||
| Q3 24 | -5.4% | 7.8% | ||
| Q2 24 | -2.3% | 10.1% | ||
| Q1 24 | -17.3% | 10.1% |
每股收益（稀释后）EXASRBA
| Q4 25 | $-0.45 | $0.53 | ||
| Q3 25 | $-0.10 | $0.43 | ||
| Q2 25 | $-0.01 | $0.53 | ||
| Q1 25 | $-0.54 | $0.55 | ||
| Q4 24 | $-4.69 | $0.58 | ||
| Q3 24 | $-0.21 | $0.36 | ||
| Q2 24 | $-0.09 | $0.54 | ||
| Q1 24 | $-0.60 | $0.53 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $531.5M |
| 总债务越低越好 | — | $2.3B |
| 股东权益账面价值 | $2.4B | $5.6B |
| 总资产 | $5.9B | $12.1B |
| 负债/权益比越低杠杆越低 | — | 0.42× |
8季度趋势，按日历期对齐
现金及短期投资EXASRBA
| Q4 25 | $964.7M | $531.5M | ||
| Q3 25 | $1.0B | $674.7M | ||
| Q2 25 | $858.4M | $710.2M | ||
| Q1 25 | $786.2M | $578.1M | ||
| Q4 24 | $1.0B | $533.9M | ||
| Q3 24 | $1.0B | $650.7M | ||
| Q2 24 | $946.8M | $599.5M | ||
| Q1 24 | $652.1M | $462.8M |
总债务EXASRBA
| Q4 25 | — | $2.3B | ||
| Q3 25 | — | $2.6B | ||
| Q2 25 | — | $2.6B | ||
| Q1 25 | — | $2.6B | ||
| Q4 24 | — | $2.6B | ||
| Q3 24 | — | $2.7B | ||
| Q2 24 | — | $2.8B | ||
| Q1 24 | — | $2.9B |
股东权益EXASRBA
| Q4 25 | $2.4B | $5.6B | ||
| Q3 25 | $2.5B | $5.5B | ||
| Q2 25 | $2.5B | $5.5B | ||
| Q1 25 | $2.4B | $5.3B | ||
| Q4 24 | $2.4B | $5.2B | ||
| Q3 24 | $3.2B | $5.2B | ||
| Q2 24 | $3.2B | $5.2B | ||
| Q1 24 | $3.1B | $5.1B |
总资产EXASRBA
| Q4 25 | $5.9B | $12.1B | ||
| Q3 25 | $5.9B | $12.2B | ||
| Q2 25 | $5.8B | $12.2B | ||
| Q1 25 | $5.7B | $11.9B | ||
| Q4 24 | $5.9B | $11.8B | ||
| Q3 24 | $6.7B | $11.9B | ||
| Q2 24 | $6.7B | $12.1B | ||
| Q1 24 | $6.4B | $12.0B |
负债/权益比EXASRBA
| Q4 25 | — | 0.42× | ||
| Q3 25 | — | 0.47× | ||
| Q2 25 | — | 0.47× | ||
| Q1 25 | — | 0.50× | ||
| Q4 24 | — | 0.50× | ||
| Q3 24 | — | 0.52× | ||
| Q2 24 | — | 0.55× | ||
| Q1 24 | — | 0.58× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $255.2M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $186.5M |
| 自由现金流率自由现金流/营收 | 13.7% | 15.5% |
| 资本支出强度资本支出/营收 | 3.6% | 5.7% |
| 现金转化率经营现金流/净利润 | — | 2.33× |
| 过去12个月自由现金流最近4个季度 | $356.8M | $719.2M |
8季度趋势，按日历期对齐
经营现金流EXASRBA
| Q4 25 | $151.7M | $255.2M | ||
| Q3 25 | $219.9M | $239.7M | ||
| Q2 25 | $89.0M | $326.5M | ||
| Q1 25 | $30.8M | $156.8M | ||
| Q4 24 | $47.1M | $184.5M | ||
| Q3 24 | $138.7M | $285.4M | ||
| Q2 24 | $107.1M | $337.3M | ||
| Q1 24 | $-82.3M | $124.8M |
自由现金流EXASRBA
| Q4 25 | $120.4M | $186.5M | ||
| Q3 25 | $190.0M | $188.5M | ||
| Q2 25 | $46.7M | $241.7M | ||
| Q1 25 | $-365.0K | $102.5M | ||
| Q4 24 | $10.7M | $127.9M | ||
| Q3 24 | $112.6M | $248.5M | ||
| Q2 24 | $71.2M | $308.6M | ||
| Q1 24 | $-120.0M | $79.6M |
自由现金流率EXASRBA
| Q4 25 | 13.7% | 15.5% | ||
| Q3 25 | 22.3% | 17.3% | ||
| Q2 25 | 5.8% | 20.4% | ||
| Q1 25 | -0.1% | 9.2% | ||
| Q4 24 | 1.5% | 11.2% | ||
| Q3 24 | 15.9% | 25.3% | ||
| Q2 24 | 10.2% | 28.2% | ||
| Q1 24 | -18.8% | 7.5% |
资本支出强度EXASRBA
| Q4 25 | 3.6% | 5.7% | ||
| Q3 25 | 3.5% | 4.7% | ||
| Q2 25 | 5.2% | 7.2% | ||
| Q1 25 | 4.4% | 4.9% | ||
| Q4 24 | 5.1% | 5.0% | ||
| Q3 24 | 3.7% | 3.8% | ||
| Q2 24 | 5.1% | 2.6% | ||
| Q1 24 | 5.9% | 4.2% |
现金转化率EXASRBA
| Q4 25 | — | 2.33× | ||
| Q3 25 | — | 2.51× | ||
| Q2 25 | — | 2.97× | ||
| Q1 25 | — | 1.38× | ||
| Q4 24 | — | 1.56× | ||
| Q3 24 | — | 3.75× | ||
| Q2 24 | — | 3.04× | ||
| Q1 24 | — | 1.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
RBA
| Buyer Revenue | $577.2M | 48% |
| Seller Revenue | $255.2M | 21% |
| CA | $199.0M | 17% |
| Other | $124.7M | 10% |
| AU | $47.3M | 4% |
